Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Net Cash Flow: 2021-2025

Historic Net Cash Flow for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -$1.7 million.

  • InMed Pharmaceuticals' Net Cash Flow fell 76.50% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 164.62%. This contributed to the annual value of $4.5 million for FY2025, which is 292.42% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Net Cash Flow of -$1.7 million as of Q3 2025, which was down 127.28% from $6.4 million recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Net Cash Flow registered a high of $8.0 million during Q3 2021, and its lowest value of -$5.4 million during Q1 2022.
  • Its 3-year average for Net Cash Flow is -$615,114, with a median of -$1.7 million in 2025.
  • Its Net Cash Flow has fluctuated over the past 5 years, first crashed by 348.26% in 2023, then surged by 721.59% in 2025.
  • Quarterly analysis of 5 years shows InMed Pharmaceuticals' Net Cash Flow stood at -$4.1 million in 2021, then surged by 164.03% to $2.6 million in 2022, then crashed by 171.02% to -$1.8 million in 2023, then fell by 17.07% to -$2.2 million in 2024, then crashed by 76.50% to -$1.7 million in 2025.
  • Its last three reported values are -$1.7 million in Q3 2025, $6.4 million for Q2 2025, and $1.3 million during Q1 2025.